Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 8, 2013, Pages 579-587

  Zhu, Rongrong ^a   Wu, Xianzheng ^b   Xiao, Yu ^a   Gao, Bo ^a   Xie, Qian ^a   Liu, Hui ^c   Wang, Shilong ^a  

^a TONGJI UNIVERSITY   (China)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; FLUOROURACIL; HYDROXIDE; LACTATE DEHYDROGENASE; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIVER CANCER; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FLUOROURACIL; HUMANS; HYDROXIDES; LIPIDS; LIVER NEOPLASMS; NANOPARTICLES;

EID: 84884581673     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1445     Document Type: Article

References (41)

1. Gusella M, Frigo AC, Bolzonella C, et al. Predictors of survival. and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal. cancer. BRIT J Cancer 2009; 100:1549.
2. Han R, Yang YM, Dietrich J, et al.. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central. nervous system. J Biol 2008;7:12.
3. Tong JT, Xie GF, He JX, et al.. Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal. Cancer. J Biomed Biotechnol 2011;10:740564.
4. Sabaawy HE, Farley T, Ahmed T, et al. Synergetic effects of retrovirus IFN-al.pha gene transfer and 5-Fu on apoptosis of colon cancer cells. Acta Haematol 1999;101:82.
5. Tsai YM, Chien CF, Lin LC, et al.. Curcumin and its nanoformulation: The kinetics of tissue distribution and bloodbrain barrier penetration. Int J Pharm 2011;416:331.
6. Strö fer M, Jelkmann W, Depping R. Curcumin decreases survival. of Hep3B liver and MCF-7 breast cancer cells: The role of HIF. Strahlenther Onkol 2011;187:393.
7. Aggarwal. BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397.
8. Choi H, Chun YS, Kim SW, et al. Curcumin inhibits hypoxiainducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: A mechanism of tumor growth inhibition. Mol Pharmacol 2006;70:1664.
9. Aggarwal. BB, Shishodia S. Suppression of the nuclear factorkappaB activation pathway by spice-derived phytochemical.s: Reasoning for seasoning. Ann N Y Acad Sci 2004; 1030:434.
10. Senft C, Polacin M, Priester M, et al. The nontoxic natural. compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against mal.ignant gliomas. BMC Cancer 2010;10:491.
11. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4:807.
12. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999;27:486.
13. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007; 595:453.
14. Bisht S, Feldmann G, Soni S, et al.. Polymeric nanoparticleencapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnol 2007; 17:1477.
15. Narayanan NK, Nargi D, Randolph C, et al.. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009;125:1.
16. Mulik RS, Mönkkönen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010;398:190.
17. Parkin DM, Bray F, Ferlay J, Pisani P. Global. cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
18. Li Y, Chen Z, Li F, et al. Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma. Int J Nanomed 2012;7:4593.
19. Mak GW, Lai WL, Zhou Y, et al.. CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells. PLoS One 2012;7:e42210.
20. Wang JL, Tang GP, Shen J, et al. A gene nanocomplex conjugated with monoclonal. antibodies for targeted therapy of hepatocellular carcinoma. Biomaterial.s 2012;33:4597.
21. Ming ZJ, Hu Y, Qiu YH, et al. Synergistic effects of betaaescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 2010;17:575.
22. Zhu RR, Qin LL, Wang M, et al. Preparation, Characterization and anti-tumor property of podophyllotoxinloaded solid lipid nanoparticles. Nanotechnology 2009;20: 055702.
23. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 2007;17:461.
24. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterial.s 2010;31:6597.
25. Gao Y, Xu P, Chen L, et al. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Int J Pharm 2010;387:263.
26. Choi SJ, Oh JM, Choy JH. Anticancer drug-layered hydroxide nanohybrids as potent cancer chemotherapy agents. J Phys Chem Sol 2008;69:1528.
27. Choi SJ, ChoyJH. Layered double hydroxide nanoparticles as target-specific delivery carriers: Uptake mechanism and toxicity. Nanomedicine 2011;6:803.
28. Guo X, Xing Y, Mei Q, et al. Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles. Anti-Cancer Drug 2012;23:185.
29. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical. strategies. Nat Rev Cancer 2003;3:330.
30. Choi MA, Kim SH, Chung WY, et al.. A natural. sesquiterpenoid from Curcuma xanthorrhiza, has an anti-metastatic potential. in experimental. mouse lung metastatic model. Biochem Biophys Res Comm 2005;326:210.
31. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxal.iplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup anal.yses of the Multicenter International. Study of Oxal.iplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.. J Clin Oncol 2012;30:3353.
32. Itokawa H, Hirayama F, Funakoshi K, et al. Studies on the antitumor bisabolane sesquiterpenoids isolated from Curcuma xanthorrhiza. Chem Pharm Bull 1985;33:3488.
33. Cheng AL., Hsu CH, Lin JK, et al. Phase 1 clinical. trial. of curcumin, a chemopreventive agent, in patients with highrisk or premal.ignant lesions. Anticancer Res 2001;21:2895.
34. Dhillon N, Aggarwal. BB, Newman RA, et al. Phase II trial. of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491.
35. Zheng N, Zhou M, Lu W. In vivo distribution of 5-Fluorouracil after peritumoral. implantation using a biodegradable micro-device in tumor-bearing mice. Eur J Drug Metab Pharmacokinet 2012 [Epub ahead of print]; DOI: 10.1007/s13318-012-0111-z.
36. Cheng MR, Li Q, Wan T, et al. Gal.actosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012;18:6076.
37. Srimuangwong K, Tocharus C, Yoysungnoen Chintana P, et al.. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 2012;18:2383.
38. Baell JB, Huang DCS. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002;64:8513.
39. Mashima T, Tsuruo T. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat 2005; 8:339.
40. Fleischer A, Ghadiri A, Dessauge F, et al. Modulating apoptosis as a target for effective therapy. Mol Immunol 2006; 43:1065.
41. Cheah YH, Nordin FJ, Sarip R, et al. Combined xanthorrhizolcurcumin exhibits synergistic growth inhibitory activity via apoptosis induction inhuman breast cancer cells MDA-MB-231. Cancer Cell Int 2009;9:1.